Lured By Rising Transplant Cases, Astellas Finally Brings Prograf To India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Japan's second-largest drug maker Astellas is bringing into India its flagship organ transplant drug Prograf (tacrolimus) in a bid to tap the Asian giant's steadily growing domestic pharmaceutical market. The product registration application for Prograf is pending with the Drug Controller General of India and Astellas hopes to launch the drug by the end of the current financial year
You may also be interested in...
Astellas/Pfizer’s COX-2 Inhibitor Celecox Gains Additional Indications In Japan
Astellas Pharma and Pfizer Japan June 17 announced additional indications for their COX-2 inhibitor Celecox (celecoxib) in Japan for lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome and tendinitis/tendosynovitis
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).